{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-043017","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.823315+00:00","generated_at":"2026-05-23T01:44:55.559462+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Armata receives $4.65M additional DoD funding for phage therapy trial; topline data Q2 2025","bullets":["Received $4.65M additional non-dilutive DoD funding for AP-SA02; total award now $26.2M.","Phase 1b/2a diSArm trial of AP-SA02 for S. aureus bacteremia enrolled 50 subjects; last visit Jan 2025.","Two subsets observed: one with in vivo phage amplification suggesting phage activity despite antibiotics.","Topline data expected in Q2 2025 to inform optimal dose for larger efficacy trial.","Going concern note in 2024 10-K remains unchanged per company disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-043017","json":"https://secwatch.observer/filing/0001104659-25-043017.json","markdown":"https://secwatch.observer/filing/0001104659-25-043017.md","text":"https://secwatch.observer/filing/0001104659-25-043017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/0001104659-25-043017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/tm2513778d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:44:55.559462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}